Monitor initial AVLAYAH sales trajectory and payer coverage decisions over the next 2 quarters; key pipeline catalysts include DNL593 data (end 2026) and DNL126 BLA filing (2027). The strong cash position and royalty funding reduce near-term dilution risk.
DNLI drugs
DNLI drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $19.62entry
- T+1 · 6mo ago +0.25%α +0.02% · $19.67
- T+5 · 6mo ago −1.17%α −2.64% · $19.39
- T+20 · 5mo ago −0.51%α −0.53% · $19.52
- T+60 · 3mo ago +23.19%α +18.35% · $24.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first medicine to cross the blood-brain barrier via transferrin receptor. The company also secured $200M in royalty financing and has a robust pipeline with key readouts expected by end of 2026.
Key Financial Metrics
Key Facts
- FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome on March 25, 2026
- First commercial patients dosed in April 2026; launch operational with payers engaged
- Received $200M gross proceeds from Royalty Pharma synthetic royalty funding agreement
- Cash, cash equivalents and marketable securities of $1.05B as of March 31, 2026
- Net loss improved to $128.4M from $133.0M year-over-year
- Pipeline progress: DNL126 (Sanfilippo) Phase 3 prep underway, DNL593 (FTD-GRN) data by end 2026, DNL628 (Alzheimer's) Phase 1b dosed
Financial Impact
AVLAYAH revenue potential uncertain but platform validation and $200M non-dilutive funding strengthen balance sheet; net loss slightly narrowed to $128.4M
Risk Factors
- AVLAYAH commercial adoption and reimbursement uncertainty in Hunter syndrome market
- Confirmatory trial (COMPASS) may affect continued approval
- Pipeline setbacks could outweigh commercial progress
- Takeda's termination of DNL593 collaboration adds development risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3290512 |
Track record
17 reports on DNLI
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +7.03% at T+60 after the Mar 25, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
- Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
- Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
- Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
- Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers